Hardman & Co’s analysts have direct experience of uncovering accounting frauds. In this article, Steve Clapham outlines why we might see a surge in them over the next few years. He is engaged by institutions to teach their fund managers and analysts how to identify risks brought about by such frauds. Hardman & Co is pleased to offer this service to private investors.

01 Aug 2018
The Monthly
Time Finance plc (TIME:LON), 59.5 | Allergy Therapeutics plc (AGY:LON), 6.8 | Arbuthnot Banking Group PLC (ARBB:LON), 935 | Avacta Group PLC (AVCT:LON), 32.5 | Burford Capital Limited (BUR:LON), 994 | City of London Investment Group PLC (CLIG:LON), 365 | TheraCryf PLC (TCF:LON), 0.3 | Genedrive Plc (GDR:LON), 1.5 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Primary Health Properties PLC (PHP:LON), 98.9 | R.E.A. Holdings plc (RE:LON), 80.0 | Scancell Holdings Plc (SCLP:LON), 10.5 | Surface Transforms PLC (SCE:LON), 1.2 | Tissue Regenix Group plc (TRX:LON), 31.0 | Titon Holdings Plc (TON:LON), 76.0 | Warpaint London PLC (W7L:LON), 470 | Oxford BioMedica plc (OXB:LON), 342 | ValiRx PLC (VAL:LON), 0.4

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
The Monthly
Time Finance plc (TIME:LON), 59.5 | Allergy Therapeutics plc (AGY:LON), 6.8 | Arbuthnot Banking Group PLC (ARBB:LON), 935 | Avacta Group PLC (AVCT:LON), 32.5 | Burford Capital Limited (BUR:LON), 994 | City of London Investment Group PLC (CLIG:LON), 365 | TheraCryf PLC (TCF:LON), 0.3 | Genedrive Plc (GDR:LON), 1.5 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Primary Health Properties PLC (PHP:LON), 98.9 | R.E.A. Holdings plc (RE:LON), 80.0 | Scancell Holdings Plc (SCLP:LON), 10.5 | Surface Transforms PLC (SCE:LON), 1.2 | Tissue Regenix Group plc (TRX:LON), 31.0 | Titon Holdings Plc (TON:LON), 76.0 | Warpaint London PLC (W7L:LON), 470 | Oxford BioMedica plc (OXB:LON), 342 | ValiRx PLC (VAL:LON), 0.4
- Published:
01 Aug 2018 -
Author:
Steve Clapham -
Pages:
40 -
Hardman & Co’s analysts have direct experience of uncovering accounting frauds. In this article, Steve Clapham outlines why we might see a surge in them over the next few years. He is engaged by institutions to teach their fund managers and analysts how to identify risks brought about by such frauds. Hardman & Co is pleased to offer this service to private investors.